Literature DB >> 19799754

A vascular access team can increase AV fistula creation in pediatric ESRD patients: a single center experience.

Deepa H Chand1, Dale Bednarz, Matthew Eagleton, Leonard Krajewski.   

Abstract

The National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF-DOQI) recommends the use of a permanent vascular access for pediatric hemodialysis (HD) patients; however, central venous catheters are the most common vascular access used among children. In children receiving HD, central venous catheters, while suboptimal, are the most common vascular access used. As such, it is imperative that pediatric HD providers optimize vascular access techniques. We report outcomes of arteriovenous fistula (AVF) creation by a single surgeon in pediatric HD patients dialyzed at a single center. We further describe our experience and outcomes with the use of the operating microscope in the United States in children receiving HD under 15 kg in weight and as young as 4 years of age. AVF usage rates as well as short- and long-term patency rates can be quite high with proper management. We further illustrate that the Fistula First principles can be applied to the pediatric population in the setting of a single surgeon with single center experience. As such, we have surpassed the current NKF-DOQI recommendation of 50% fistula use in prevalent HD patients.

Entities:  

Mesh:

Year:  2009        PMID: 19799754     DOI: 10.1111/j.1525-139X.2009.00638.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  9 in total

1.  A comparison of arteriovenous fistulas and central venous lines for long-term chronic haemodialysis.

Authors:  Alison Ma; Rukshana Shroff; Daljit Hothi; Marina Munoz Lopez; Faidra Veligratli; Francis Calder; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2012-10-06       Impact factor: 3.714

2.  Autologous arteriovenous fistulas for hemodialysis using microsurgery techniques in children weighing less than 20 kg.

Authors:  Vasiliki Karava; Pascal Jehanno; Theresa Kwon; Georges Deschênes; Marie-Alice Macher; Pierre Bourquelot
Journal:  Pediatr Nephrol       Date:  2017-12-05       Impact factor: 3.714

3.  Permanent vascular access survival in children on long-term chronic hemodialysis.

Authors:  Liliana Briones; Alexia Diaz Moreno; Sergio Sierre; Laura Lopez; José Lipsich; Marta Adragna
Journal:  Pediatr Nephrol       Date:  2010-06-02       Impact factor: 3.714

4.  Good outcomes for arteriovenous fistula with buttonhole cannulation for chronic hemodialysis in children and adolescents.

Authors:  Brittany Garza; Jessica Geer; Sarah J Swartz; Poyyapakkam Srivaths; Tam T T Huynh; Eileen D Brewer
Journal:  Pediatr Nephrol       Date:  2022-05-05       Impact factor: 3.714

Review 5.  Practical aspects of arteriovenous fistula formation in the pediatric population.

Authors:  Miriam Manook; Francis Calder
Journal:  Pediatr Nephrol       Date:  2012-10-27       Impact factor: 3.714

6.  Reducing central venous catheters in chronic hemodialysis--a commitment to arteriovenous fistula creation in children.

Authors:  Rossana Baracco; Tej Mattoo; Amrish Jain; Gaurav Kapur; Rudolph P Valentini
Journal:  Pediatr Nephrol       Date:  2014-01-29       Impact factor: 3.714

Review 7.  Update on the creation and maintenance of arteriovenous fistulas for haemodialysis in children.

Authors:  Evgenia Preka; Rukshana Shroff; Lynsey Stronach; Francis Calder; Constantinos J Stefanidis
Journal:  Pediatr Nephrol       Date:  2020-10-15       Impact factor: 3.714

8.  Outcomes of Arteriovenous Fistula for Hemodialysis in Pediatric and Adolescent Patients.

Authors:  Suh Min Kim; Seung-Kee Min; Sanghyun Ahn; Sang-Il Min; Jongwon Ha
Journal:  Vasc Specialist Int       Date:  2016-09-30

9.  A dedicated vascular access clinic for children on haemodialysis: Two years' experience.

Authors:  Rukshana Shroff; Rosalie B Sterenborg; Adam Kuchta; Andrew Arnold; Nicholas Thomas; Lynsey Stronach; Soundrie Padayachee; Francis Calder
Journal:  Pediatr Nephrol       Date:  2016-08-07       Impact factor: 3.714

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.